Cystic Fibrosis Awareness Month
Cystic Fibrosis (CF) is a rare disease that causes breathing and digestive problems; patients have thick and sticky mucus that blocks airways and eventually limits their ability to breathe over time. Around 35,000 people in the United States suffer from CF, and in recent years, treatments and life expectancy has greatly improved. There is not a cure for CF, but treatments ease symptoms, reduce complications, and improve quality of life. The goals of CF treatments are to prevent and control lung infections, remove and loosen mucus from the lungs, treat and prevent intestinal blockage, and provide adequate nutrition.
Treatment Options
- Bronchodilators: Inhaled medications that keep airways open by relaxing the muscles around the bronchial tubes.
- Oral Pancreatic Enzymes: Help the digestive tract to absorb nutrients and keep the body strong and acid-reducing medications to help pancreatic enzymes work better.
- CFTR Modulator Therapies: Medications that target protein defects caused by mutations and help these proteins function better. This class of medications have been developed over the last ten years and are considered a major achievement in treatment.
How we help CF patients
Here at Maxor Specialty we are limited distribution providers of both inhaled medications and medications that target gene mutations, including Trikafta®, Kalydeco®, Orkambi®, Symdeko®, Arikayce®, and VALTOCO®. We specialize in rare diseases like CF and part of our care coordination plan for these patients is to collaborate with each point in the health system to provide better outcomes. For example, we work directly with physicians to coordinate all aspects of patient care including refill reminders and education. Our proactive, personalized care coordination has led to best in case adherence rates and improved patient quality of life. Our member services team are always there to support our patients providing them with the safety and attention they need. For more information on how we help patients with CF, please contact Bill Aikins at [email protected].
